Introduction {#s1}
============

Telomeres are repetitive nucleotide sequences that cap linear chromosomes. The normal telomere shortening that occurs with cellular division can eventually trigger cell senescence or apoptosis \[[@C1]\]. Individuals with short telomeres, with or without associated telomere-related mutations, are more susceptible to a range of premature organ dysfunctions, including interstitial lung disease (ILD) \[[@C2]--[@C6]\]. The most definitive treatment for ILD and other advanced lung diseases that progress despite standard therapy is lung transplantation.

Long-term survival following lung transplantation remains limited because of chronic lung allograft dysfunction (CLAD) \[[@C7]\]. While post-transplant events such as primary graft dysfunction or cytomegalovirus (CMV) pneumonitis are associated with CLAD, there are limited biomarkers to predict which patients are at highest risk for CLAD development \[[@C8]--[@C10]\]. Several case series and retrospective cohort studies have suggested that individuals with short telomeres and ILD have worse outcomes following lung transplantation, including decreased CLAD-free survival \[[@C11]--[@C14]\]. The mechanisms behind this association are unclear and may be related to an inability to tolerate immunosuppression because of limited bone-marrow reserve \[[@C11], [@C15]\]. It is unknown whether post-transplant telomere length and/or rate of telomere attrition are associated with worse outcomes or whether it is only pre-transplant short telomeres that are predictive. It is also unknown whether telomere length is associated with post-transplant course in diseases other than ILD.

The objective of this study was to assess the relationship between early post-transplant telomere length as well as the rate of post-transplant telomere attrition and outcomes following lung transplantation, including CLAD-free survival, for all recipients, regardless of native lung disease.

Methods {#s2}
=======

Study population {#s2a}
----------------

This was a single-centre prospective cohort study. All patients who underwent lung transplantation between June 1, 2014 and November 1, 2018 were eligible to participate. Recipients underwent solumedrol and basiliximab induction and were maintained on a combination of a calcineurin inhibitor (most commonly tacrolimus), a cell cycle inhibitor (most commonly mycophenolate mofetil), and prednisone. Recipients who developed leukopenia, defined as white blood cell count \<3.0 cells·µL^−1^ first had a reduction in the dose of their cell cycle inhibitor or cessation of antiviral prophylaxis (where appropriative). Recipients who developed absolute neutrophil count \<1000 cells·µL^−1^ were treated with granulocyte colony-stimulating factor (G-CSF).

Patients who provided written informed consent had blood collected during the first post-transplant year at the time of routine surveillance outpatient bronchoscopies (typically 1, 3, 6, and 12 months). Patients who did not provide informed consent were not eligible to participate. The Institutional Review Board approved this study.

Telomere length measurement {#s2b}
---------------------------

Relative telomere length was measured from recipient peripheral blood using a high throughput monoplex real-time quantitative (qPCR) assay \[[@C16]\]. qPCR was chosen to measure telomere length, in part, because it treats telomere length as a continuous variable (as opposed to an absolute cut-off such as \<10th percentile of telomere length for age). This allows for detection of clinically relevant observations that may not be apparent in a cohort where telomere length is treated as a categorical variable.

The qPCR assay calculates the ratio between a recipient\'s telomeric repeat copy number (T) and a single copy reference gene (36B4) (S) by subtracting the average 36B4 threshold cycle value from the average telomere threshold cycle value (see [Supplemental Material](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00003-2020.figures-only#fig-data-supplementary-materials) for further details). Subtracting the T/S ratio of a reference sample, consisting of a pooled genomic DNA sample, from the recipient\'s T/S ratio allows calculation of the relative T/S ratio. In this way, the relative T/S is defined in relation to a population reference curve. Final measurements are exponentiated to assure normality \[[@C17]\]. So, for example, a patient with an exponentiated telomere length of 1.2 would have a telomere length 20% longer than the pooled population reference sample. A telomere length of 0.8 would be 20% shorter than the pooled reference sample.

Our primary focus was on recipients with available early post-transplant samples. Early was defined as within the first 100 days post-transplant, with this time point chosen to avoid confounding by the effects of post-transplant immunosuppression, which is associated with telomere attrition, and to avoid enriching the cohort for cases in which outcomes (for example, CMV viraemia) occurred before telomere length measurement \[[@C18]--[@C20]\]. Recipients with early post-transplant samples were divided into those with long (third tertile) and short (first tertile) telomeres as previously described \[[@C21], [@C22]\]. For recipients with two or more samples available, change in telomere length over time was calculated. Recipients were then divided into those with the highest tertile telomere loss over time *versus* recipients in the other tertiles.

Study outcomes {#s2c}
--------------

The primary outcome was CLAD-free survival following transplant. CLAD was defined according to international consensus guidelines \[[@C23]\]. Secondary outcomes included time to: 1) leukopenia requiring cessation of immunosuppression or antiviral medication; 2) leukopenia requiring G-CSF; 3) chronic kidney disease (CKD) stage 3B or higher; 4) liver injury, defined as alanine aminotransferase or aspartate aminotransferase greater than three times the upper limit of normal (129 and 183 U·L^−1^, respectively); 5) CMV viraemia \>1000 copies·mL^−1^ with or without end-organ involvement; 6) acute cellular rejection (ACR) of any grade. Additional outcomes included ACR score (defined as the sum of the A grades on each biopsy divided by the total number of biopsies) and airway rejection (BCR) score (defined as the sum of the B grades on each biopsy divided by the total number of biopsies). Recipients for whom the secondary outcome occurred before telomere length was measured were excluded from that particular analysis.

Statistical analysis {#s2d}
--------------------

Selected demographic and clinical variables were analysed using descriptive statistics. For our primary outcome analysis, we used a Cox proportional hazard model to assess the relationship between early post-transplant telomere length and CLAD-free survival. For the purposes of this analysis, we treated telomere length as a continuous variable (defined as the percentage that the patient\'s telomere length was above or below the pooled reference sample in 5% increments) and separately, as a categorical variable (longest and shortest tertile of telomere length). We included other covariates associated with CLAD-free survival in an adjusted model, including age, native lung disease, lung allocation score (LAS), bilateral transplant status, and ACR score. We also used unadjusted Cox proportional hazard models to assess the relationship between early post-transplant telomere length and various secondary outcomes. The proportional hazard assumptions were confirmed using Schoenfeld residuals.

In a sensitivity analysis, we included the first telomere length available for all patients (not just those taken in the first 100 days) and used Cox proportional hazard models to assess hazard of subsequent CLAD-free survival (from the time of last telomere length measurement). Finally, for patients with two or more samples, we calculated absolute change in telomere length and change in telomere length over time. We then compared subsequent CLAD-free survival (from the time of last telomere length measurement) between those in the bottom tertile of telomere attrition (fastest telomere loss) and other recipients using a Cox proportional hazard model. All analyses were performed using Stata version 15 (Stata Corp, College Station, TX, USA).

Results {#s3}
=======

Study cohort {#s3a}
------------

There were 215 patients who underwent lung transplant during the study enrolment period, 98 (45.6%) of whom consented to participate and had at least one blood sample collected that was of sufficient quality for telomere length analysis ([figure 1](#F1){ref-type="fig"}). There were no significant differences in age, LAS at transplant, or native lung disease between those who did and did not consent. Characteristics of the included recipients are listed in [table 1](#TB1){ref-type="table"}. The median number of telomere length measurements per recipient was 2 (interquartile range (IQR)=1--3). The median follow-up time was 2.2 years (IQR=1.3--2.7 years). During the follow-up time 17 (24.6%) recipients developed CLAD stage 1 or higher and 4 (5.8%) died. Additional outcome events are listed in [table 2](#TB2){ref-type="table"}.

![Study cohort. There were 37 recipients who had both an early telomere length measurement and two or more telomere lengths measured post-transplant.](00003-2020.01){#F1}

###### 

Study cohort characteristics

  ---------------------------------------------------------- -------------------
  **Patients n**                                             69
  **Age years**                                              57.9 (50.1--64.5)
  **Female**                                                 23 (33.3)
  **Native lung disease**                                    
   Interstitial lung disease                                 32 (46.4)
   Chronic obstructive pulmonary disease                     18 (26.1)
   Cystic fibrosis                                           13 (18.8)
   Other                                                     6 (8.6)
  **Lung allocation score at the time of transplantation**   37.3 (33.5--48.5)
  **Wait time days**                                         181 (38--416)
  **Longest ischaemic time min**                             266 (214--317)
  **Cardiopulmonary bypass**                                 62 (89.9)
  **Cytomegalovirus donor positive, recipient negative**     27 (39.1)
  **Bilateral transplant**                                   57 (82.6)
  **Mechanical ventilation \>5** **d post-transplant**       8 (11.6)
  **Length of index hospitalisation days**                   15 (13--20)
  **Follow-up time years**                                   2.2 (1.3--2.7)
  ---------------------------------------------------------- -------------------

Data are presented as median (interquartile range) or n (%), unless otherwise stated.

###### 

Study cohort outcomes

  ------------------------------------------------------------------------ -------------
  **Patients n**                                                           69
  **Leukopenia requiring adjustment of immunosuppression or antivirals**   32 (46.4)
  **Leukopenia requiring G-CSF**                                           17 (24.6)
  **Chronic kidney disease stage 3B or higher**                            27 (39.1)
  **CMV viraemia or end-organ damage**                                     11 (15.9)
  **ACR (any)**                                                            31 (44.9)
  **ACR score**                                                            0 (0--0.50)
  **BCR score**                                                            0 (0--0)
  **Chronic lung allograft dysfunction (stage 1 or higher)**               17 (24.6)
  **Died**                                                                 4 (5.8)
  ------------------------------------------------------------------------ -------------

Data are presented as median (interquartile range) or n (%), unless otherwise stated. ACR: acute cellular rejection; BCR: airway rejection; CMV: cytomegalovirus; G-CSF: granulocyte colony-stimulating factor

Early post-transplant telomere length and CLAD-free survival {#s3b}
------------------------------------------------------------

Among included recipients, 56 (81.1%) had telomere length measured within the first 100 days post-transplant (median time to measurement 43 days (IQR=33--78 days)) ([figure 1](#F1){ref-type="fig"}). The median recipient telomere length was 0.87 (IQR=0.76--0.97) or 14% shorter than the reference pool. Recipients in the shortest tertile of telomere length (68.4% of whom had ILD) had a mean relative telomere length=0.68 (range 0.38--0.78) ([table S1](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00003-2020.figures-only#fig-data-supplementary-materials)). Those in the longest tertile of telomere length had a mean relative telomere length=1.06 (range 0.94--1.31). Age and early post-transplant telomere length were strongly and inversely correlated (r=−0.57, p\<0.001). Correlation was noted for both non-ILD (r=−0.72, p\<0.001) and ILD patients (r=−0.35, p=0.07).

Early telomere length, treated as a continuous variable, was associated with decreased CLAD-free survival on unadjusted analysis (hazard ratio (HR)=1.24, 95% CI=1.07--1.44, p=0.004) ([table 3](#TB3){ref-type="table"}). By way of interpretation, this indicates that a 5% decrease in telomere length compared to the population reference pool was associated with a 24% worse hazard of CLAD-free survival. This relationship persisted after adjusting for age, native lung disease, LAS score, bilateral transplant status, and ACR score (HR=1.24, 95% CI=1.04--1.48 p=0.02). There was improved adjusted CLAD-free survival in recipients in the longest tertile of telomere length compared to the other tertiles (HR=0.08, 95% CI=0.007--0.944, p=0.04). Finally, when restricting our analysis to cases of definitive stage 1 or higher CLAD, as characterised in the new CLAD consensus guidelines, early post-transplant telomere length was associated with worse definitive CLAD-free survival on unadjusted (HR=1.20, 95% CI=1.02--1.40, p=0.02) and adjusted analysis (HR=1.21, 95% CI=1.01--1.44, p=0.03) ([Supplemental Table 2](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00003-2020.figures-only#fig-data-supplementary-materials)) \[[@C24]\].

###### 

Relationship between early post-transplant telomere length^\#^ and time to specified post-transplant outcomes (n=56)

                                                                                                                                                                                         **Hazard ratio**     **95% CI**   **p-value**
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------ -------------- -------------
  **Leukopenia requiring cessation of immunosuppression or antiviral prophylaxis medications**                                                                                                                             
   Telomere length^¶^                                                                                                                                                                    1.09                 0.98--1.22   0.13
   Shortest telomeres^+^                                                                                                                                                                 1.67                 0.76--3.69   0.20
   Longest telomeres^§^                                                                                                                                                                  0.60                 0.24--1.50   0.27
  **Leukopenia requiring granulocyte colony-stimulating factor**                                                                                                                                                           
   Telomere length                                                                                                                                                                       1.17                 1.01--1.35   0.03
   Shortest telomeres                                                                                                                                                                    2.97                 1.03--8.55   0.04
   Longest telomeres                                                                                                                                                                     0.55                 0.15--1.97   0.36
  **Chronic kidney disease stage 3B or higher**                                                                                                                                                                            
   Telomere length                                                                                                                                                                       1.02                 0.92--1.13   0.68
   Shortest telomeres                                                                                                                                                                    0.61                 0.24--1.54   0.30
   Longest telomeres                                                                                                                                                                     0.86                 0.37--2.02   0.74
  **Cytomegalovirus viraemia or end-organ damage**                                                                                                                                                                         
   Telomere length                                                                                                                                                                       1.13                 0.93--1.37   0.19
   Shortest telomeres                                                                                                                                                                    2.43                 0.70--8.41   0.16
   Longest telomeres                                                                                                                                                                     0.45                 0.09--2.13   0.32
  **Acute cellular rejection (any)**                                                                                                                                                                                       
   Telomere length                                                                                                                                                                       1.00                 0.90--1.11   0.96
   Shortest telomeres                                                                                                                                                                    0.75                 0.31--1.83   0.54
   Longest telomeres                                                                                                                                                                     1.15                 0.50--2.64   0.74
  **Chronic lung allograft dysfunction-free survival (unadjusted)**                                                                                                                                                        
   Telomere length                                                                                                                                                                       1.24                 1.07--1.44   0.004
   Shortest telomeres                                                                                                                                                                    2.34                 0.75--7.28   0.14
   Longest telomeres                                                                                                                                                                     0.15                 0.02--1.16   0.07
  **Chronic lung allograft dysfunction-free survival (adjusted for age, native lung disease, lung allocation score, bilateral transplant status, and acute cellular rejection score)**                                     
   Telomere length                                                                                                                                                                       1.24                 1.04--1.48   0.02
   Shortest telomeres                                                                                                                                                                    1.79                 0.50--6.43   0.37
   Longest telomeres                                                                                                                                                                     0.08                0.007--0.944  0.04

^\#^: As measured within the first 100 days of transplant; ^¶^: Based on the percent above or below the telomere length of the reference sample; ^+^: Defined as shortest tertile of telomere length (mean relative telomere length 0.68, overall range 0.38--0.78); ^§^: Defined as longest tertile of telomere length (mean relative telomere length 1.06, overall range 0.94--1.31).

In the sensitivity analysis, the relationship between telomere length and subsequent CLAD-free survival persisted when including all recipients, regardless of time in the first year that telomere length was measured (HR=1.15, 95% CI=1.02--1.29, p=0.02). Among all recipients, those with longer telomere length had improved CLAD-free survival (HR=0.18, 95% CI=0.04--0.79, p=0.02) ([figure 2](#F2){ref-type="fig"}).

![Relationship between chronic lung allograft dysfunction-free survival following telomere length measurement in recipients in the longest tertile of telomere length compared to other recipients (hazard ratio=0.18, 95% confidence interval=0.04--0.79, p=0.02).](00003-2020.02){#F2}

Early post-transplant telomere length and other outcomes {#s3c}
--------------------------------------------------------

Early post-transplant telomere length, treated as a continuous variable, was associated with leukopenia requiring G-CSF (HR=1.17, 95% CI=1.03--8.55, p=0.03). By way of interpretation, this indicates that a 5% decrease in telomere length compared to the population reference pool was associated with a 17% increase in hazard for leukopenia requiring G-CSF. This was particularly true for recipients in the shortest tertile of telomere length (HR=2.97, 95% CI=1.02--8.57, p=0.04). Including age as a covariate in this analysis did not significantly alter the relationship between shortest telomeres and leukopenia requiring G-CSF (HR=3.17, 95% CI=1.00--10.1, p=0.05). Telomere length (treated as a continuous or categorical variable) was not associated with CKD 3B or higher, CMV viraemia, or ACR. Among the 26 CMV-mismatched recipients, those with the shortest tertile of telomere length had an increased hazard for viraemia (HR=4.04, 95% CI=1.05--15.5, p=0.04).

There were insufficient numbers of patients started on dialysis in the cohort to calculate the relationship between telomere length and time to dialysis. There were also insufficient numbers of patients with significantly elevated transaminases to calculate the relationship between telomere length and transaminitis. There was no relationship between ACR score (r=−0.04, p=0.75) or BCR score (−0.15, p=0.25) and telomere length treated as a continuous variable. There was no relationship between ACR score (p=0.89) or BCR score (p=0.48) and shortest telomere length. There was no relationship between ACR score (p=0.41) or BCR score (p=0.30) and longest telomere length.

Change in telomere length over time {#s3d}
-----------------------------------

There were 50 patients who had two or more telomere length measurements available post-transplant (median measurements=2, IQR 2--3). One patient developed CLAD before the second telomere length was measured and was excluded from the attrition analysis. The median change in telomere length per post-transplant month was −0.003 (or a 0.3% decline in relative telomere length) (IQR=−0.014 to 0.005). The median change in telomere length in the tertile of the most rapid decliners was 2.5% per month (IQR=1.6% to 3.4%). Early post-transplant length was strongly correlated with subsequent post-transplant attrition, such that recipients with longer telomeres had more rapid attrition (r=−0.38, p=0.02). The two patients with the largest increase in telomere length were both being treated for a *Pseudomonas aeruginosa* pulmonary infection at the time that the second sample was acquired.

Patients with more rapid loss in telomere length (defined as the highest tertile of loss of telomere length over time post-transplant) did not have worse subsequent CLAD-free survival on unadjusted (HR 1.70, 95% CI=0.55--5.28, p=0.36) or adjusted analysis (HR=1.38, 95% CI=0.27--7.01, p=0.70) ([figure 3](#F3){ref-type="fig"}).

![Relationship between chronic lung allograft dysfunction-free survival in patients with and without more rapid rates of telomere loss in the first post-transplant year (unadjusted hazard ratio=1.70, 95% confidence interval=0.55--5.28, p=0.36) or adjusted analysis (hazard ratio=1.38, 95% confidence interval=0.27--7.01, p=0.70).](00003-2020.03){#F3}

Discussion {#s4}
==========

Although previous studies suggest that pre-lung transplant telomere length is associated with worse post-transplant outcomes, particularly decreased CLAD-free survival, the relationship between post-transplant telomere length and transplant-related outcomes has not been well-characterised, particularly across native lung disease groups \[[@C11]--[@C14]\]. In this single-centre prospective cohort study, we found that early post-transplant length was associated with clinically significant leukopenia and decreased CLAD-free survival, independently of age or underlying lung disease.

As in other nontransplant cohort studies, telomere length was strongly correlated with patient age \[[@C21], [@C25]\]. In this context, the median telomere length of our cohort (0.86) was not dramatically lower than what would be expected given the median age (58 years). Because previous studies on telomeres in transplant patients have used different measures of telomere length (*e.g.* flow cytometry fluorescence *in situ* hybridisation) \[[@C12]\], emphasised telomere-related mutations rather than telomere length \[[@C14]\], or focused on donor rather than recipient telomere length \[[@C26]\], it is difficult to directly compare our study population with existing literature. The fact that telomere length was associated with significant leukopenia, however, suggests that measurements in our cohort are an accurate reflection of clinically meaningful bone-marrow reserve.

The relationship between telomere length and/or telomere-related mutations and CLAD has been explored previously \[[@C11]--[@C14]\]. Our study expands on this literature in several ways. First, we did not restrict our analysis to those with very short telomeres (or short telomere syndromes). By treating telomere length as a continuous variable, we were able to demonstrate that telomere length is associated with decreased CLAD-free survival beyond recipients with short telomeres or telomere-related mutations \[[@C14]\]. Second, we included recipients with any native lung disease, not just ILD. This expands the applicability of telomere-related research in lung transplant recipients. Third, we assessed telomere length in the early post-transplant period rather than based on pre-transplant samples, suggesting that post-transplant telomere length may also serve as a marker for decreased CLAD-free survival. Unfortunately, we did not routinely measure telomere length pre-transplant so we do not know to what extent pre- and post-transplant telomere length correlate or whether our findings would have been similar using pre-transplant telomere length alone.

There are several possible explanations for the observed association between early post-transplant telomere length and CLAD-free survival. Although recipients with shorter telomere length were not at increased risk for leukopenia requiring cessation of immunosuppression, there was increased need for G-CSF in this population. This degree of leukopenia may have predisposed these individuals to infections, including respiratory viral infections that, in turn, contributed to the development of CLAD \[[@C27], [@C28]\]. Alternatively, individuals with short telomeres may have reduced or impaired capacity to populate their allograft with recipient-derived stem cells \[[@C29]\]. Identification of differences in recipient cell populations in allografts of short and long telomere recipients could help better assess this hypothesis. Reassuringly, an association between early post-transplant telomere length and CLAD-free survival was also observed when considering only cases of definitive CLAD, as defined in new consensus guidelines \[[@C24]\]. Future studies should, however, collect data on total lung capacity to allow for better characterisation of restrictive CLAD, as also recommended in the guidelines.

Similarly to P[opescu]{.smallcaps} *et al.* \[[@C30]\], we found that CMV-mismatched recipients with shorter telomere length had an increased hazard of CMV viraemia. Early case series of short telomere recipients also found a higher than expected incidence of transaminitis and kidney injury, which we did not observe \[[@C13], [@C15]\]. Finally, we found no relationship between early telomere length and ACR or ACR score. This contrasts with a previous study in which we found that shorter recipient telomere length (as measured in explanted lungs) was associated with reduced risk of ACR \[[@C31]\]. Differences in tissue assessed (explant *versus* peripheral blood), sample size, or event rate may account for the different findings in this study.

There are limited data for comparison of expected telomere attrition in the transplant population. Telomere shortening was more significant in our cohort than in other nontransplant populations, where telomere attrition is typically measured over years or decades rather than months \[[@C32]\]. Similarly to large nontransplant cohorts, however, approximately 20% of recipients showed a significant increase in telomere length over time \[[@C33]\]. This may be related to epigenetic regulation with secondary effects on telomere maintenance. Alternatively, acute infection or inflammation may result in mobilisation of quiescent haematopoietic cells and proliferation of peripheral blood mononuclear cells of longer telomere length, causing a transient elevation in average telomere length \[[@C34], [@C35]\]. As with other studies, telomere attrition was directly related to starting telomere length, which could explain why the rate of telomere attrition during the first year was not associated with CLAD-free survival \[[@C34]\]. Alternatively, the more rapid attrition in the longer telomere population may have represented regression to the mean. We note that the relatively small size of the telomere attrition group and the relatively short interval follow-up indicates that we were only powered to detect large effects on CLAD-free survival. It may be that a larger cohort or assessment over a longer period would identify either telomere stability or significant ongoing loss as a better marker of subsequent risk.

As with all other cohort studies involving telomere length and lung transplant outcomes, we do not know whether the development of specific management protocols for individuals with short telomeres could improve post-transplant CLAD and/or survival. Such protocols might include lower initial immunosuppression doses, particularly cell cycle inhibitors, more frequent laboratory monitoring for developing leukopenia, and extended duration of CMV prophylaxis in mismatched recipients. Although research on the relative impact of mechanistic target of rapamycin (mTOR) *versus* calcineurin inhibitors on telomere shortening is ongoing, there are some data that mTOR inhibitors may result in less shortening \[[@C19], [@C20]\]. We believe, however, that it would be premature to consider the clinical use of potential telomere lengthening therapies such as danazol or lithium outside of research trials \[[@C36], [@C37]\].

Limitations {#s4a}
-----------

As with other reports on telomere length and lung transplant outcomes, this was a single-centre study with a relatively small sample size and limited follow-up time, particularly given that the incidence of CLAD increases with time. Because we only enrolled patients who could provide informed consent at the time of outpatient bronchoscopies, we did not capture early deaths, recipients with prolonged index hospitalisation who did not have transbronchial biopsies, or those who were unable or unwilling to provide consent. In addition, while our chosen approach to telomere measurements (real-time PCR) allows us to treat telomere length continuously, there have been concerns about its interlaboratory reliability, particularly with regard to differences in temperature storage, DNA concentration, and purification \[[@C38], [@C39]\]. While interlaboratory differences may limit between-study comparisons, there is no evidence that there is dramatic intra-laboratory variability, particularly when samples are handled using the same methodological approach in an experienced core facility with appropriate controls \[[@C40]--[@C42]\]. Consensus on the appropriate telomere length assay (including the use of more sophisticated techniques such as telomere shortest length assay, which can identify the telomere length of all chromosomes) would be beneficial for future research. Finally, we did not have data on additional transplant outcomes such as primary graft dysfunction, antibody-mediated rejection, malignancy, or major bacterial or fungal infections that may be relevant to telomere length.

Conclusions {#s4b}
-----------

Early post-transplant telomere length is associated with decreased CLAD-free survival and clinically significant leukopenia in lung transplant recipients, regardless of native lung disease.
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